👋 Hey, let’s get into it. Psychedelics just got a VIP pass.

President Trump ordered the FDA to fast-track reviews of psychedelic drugs for serious mental illness. The push includes priority vouchers for serotonin 2A agonists, with compounds like psilocybin and LSD suddenly sitting much closer to approval pathways.

The wild part? This wasn’t driven by a traditional pharma lobby. It was sparked, at least in part, by a conversation with Joe Rogan about ibogaine. Welcome to biotech in 2026, where Oval Office policy and podcast discussions are starting to blur.

💰 Lilly Bets Up to $7B on In Vivo CAR-T
Eli Lilly is not just buying a therapy, it’s buying a platform. In its up to $7 billion acquisition of Kelonia Therapeutics, the real prize is iGPS, a gene delivery system designed to generate CAR-T cells directly inside the patient’s body. Instead of extracting, engineering, and reinfusing cells through a complex and expensive process, iGPS uses lentiviral particles to deliver the genetic instructions in vivo, potentially turning CAR-T into a scalable, off-the-shelf treatment. If it works, this could dramatically lower costs, expand access, and unlock use in earlier lines of therapy. That’s the upside. The catch is that in vivo CAR-T is still largely unproven, and Lilly is stepping into a high-risk race against well-funded competitors chasing the same goal.

🇨🇳 Biogen Expands China Bet With $850M Deal
Biogen is doubling down on immunology in China, signing an $850 million biobucks deal with TJ Biopharma for rights to felzartamab. The late-stage CD38 antibody is already in Phase 3 trials across multiple indications, and Biogen is taking control of development, manufacturing, and commercialization in Greater China. The deal includes $100 million upfront with the rest tied to milestones and royalties. It’s another signal that large biotechs are getting more aggressive about regional control in key global markets.

🤖 OpenAI Launches GPT-Rosalind for Biotech
OpenAI is pushing deeper into life sciences with GPT-Rosalind, a model built specifically for biology, drug discovery, and translational research. Named after DNA pioneer Rosalind Franklin, the system aims to shrink the 10–15 year drug development timeline by helping researchers process massive datasets and uncover hidden connections faster. It’s currently available in a research preview, with plans to expand capabilities over time.

🧠 UCB Drops $1B+ to Enter Regenerative Medicine
UCB is expanding beyond epilepsy with the acquisition of Neurona Therapeutics in a deal worth over $1 billion. The centerpiece is NRTX-1001, a neuronal cell therapy designed to restore balance in overactive brain circuits by delivering GABA-producing cells directly into the brain. Early trials are targeting drug-resistant epilepsy, but the broader play is clear: UCB wants a foothold in regenerative medicine.

🩸 Novo Nordisk Eyes FDA Filing After Sickle Cell Win
Novo Nordisk is gearing up for an FDA submission after strong Phase 3 data for etavopivat in sickle cell disease. The once-daily pill reduced painful vaso-occlusive crises by 27% and significantly improved hemoglobin levels compared to placebo. Patients also went nearly twice as long before experiencing their first crisis. With both primary endpoints hit, Novo is positioning the drug as a potential cornerstone in its rare disease portfolio.

💊 Lilly’s Foundayo Targets Diabetes Next
New data shows non-inferiority to insulin with better weight loss and cardiovascular outcomes, setting up an FDA filing by Q2.

💰 Kailera Raises $625M in IPO
The obesity-focused biotech just pulled off the largest IPO in years, signaling investor appetite isn’t completely dead.

🫁 AstraZeneca’s COPD Bet Keeps Winning
Tozorakimab notched its third phase 3 win, strengthening its case as a potential blockbuster IL-33 inhibitor.

📉 Early-Stage Funding Slows Again
First-time biotech financings are trending toward pre-pandic lows as investors continue favoring later-stage companies.

🏛️ Trump Picks New CDC Director
Erica Schwartz, a former deputy surgeon general, is tapped to lead the agency pending Senate confirmation.

💈 Nektar Stock Jumps 25%
Its alopecia drug showed continued hair growth in extension data, giving investors renewed confidence.

🫁 Merck’s PD-1/VEGF Combo Looks Competitive
Early lung cancer data suggests it could rival leaders, but questions remain heading into later trials.

🌏 Aligos Strikes $445M China Deal
The biotech offloads regional rights to its HBV drug, securing cash and milestone upside.

The FDA is reopening the door to one of the most controversial corners of modern medicine, and politics is very much in the room.

This summer, the agency will convene an advisory committee to evaluate whether several widely used but unapproved peptides should be allowed to be compounded and distributed more broadly. These include compounds like BPC-157, which has built a massive following online for its supposed healing and anti-inflammatory effects despite limited clinical evidence.

What’s changed isn’t the science. It’s the leadership.

Health and Human Services Secretary Robert F. Kennedy Jr., a central figure behind the Make America Healthy Again (MAHA) movement, has been openly supportive of peptides and has even said he’s used them personally. He and several high-profile supporters have framed current FDA restrictions as government overreach that pushed patients into an unregulated gray market filled with questionable overseas products.

That argument is now shaping policy.

Just a few years ago, the FDA moved to restrict many of these same peptides, citing risks ranging from organ damage to potential cancer links. Most have never gone through the traditional approval process, meaning there’s little reliable data on safety or efficacy. Now, the agency is considering reversing course by removing some peptides from its high-risk list and potentially allowing compounding pharmacies to produce them under looser oversight.

Supporters say this could bring demand back into regulated channels and reduce reliance on black market supply. Critics see something else entirely.

Former regulators and researchers warn that easing access without strong clinical evidence risks undermining the entire drug approval system. If therapies can reach patients through alternative pathways, it raises a bigger question: why would companies invest billions into rigorous trials at all?

The broader concern is consistency. At the same time the FDA is tightening standards in areas like vaccines, it’s exploring more flexibility for products with far less data behind them. To some, that looks less like modernization and more like ideology creeping into regulation.

One thing is clear: peptides are no longer a fringe wellness trend. They’ve become a policy flashpoint, and whatever the FDA decides next could reshape how experimental therapies move from hype to the clinic.

That’s how many patients received prescriptions for Lilly’s oral obesity drug Foundayo in its first week. It trails Novo’s oral Wegovy launch with 3,000+ patients in week 1, but analysts caution the comparison may not be apples-to-apples given different rollout timelines.

Here’s what biotech Redditors are talking about:

🤩 The “Holy Grail” Biotech Employer
A Reddit thread asked which company is the ultimate place to work in biotech. You might have expected names like Lilly, Pfizer, or J&J to dominate… but they didn’t. The most popular answer? New England Biolabs. The reasons were surprisingly consistent: strong work-life balance, standout benefits, and a culture that actually feels sustainable. Think fully covered health insurance, high-quality meals, and perks that go beyond the usual corporate playbook. In biotech, prestige might get attention, but quality of life is what keeps people there long term.

😬 New PhD, Six Months, No Job
One recent immunology PhD shared they’ve been unemployed for over six months, sparking a brutally honest discussion. Some pointed to a frozen hiring market and oversupply of highly qualified candidates. Others questioned the ROI of a PhD altogether, arguing earlier industry entry or alternative paths might offer better long-term outcomes. A few even said they’d choose med school or trade school if they could do it over. Not exactly the post-grad glow-up people imagine.

🏭 BMS Layoffs Hit Again
Another 206 employees cut in New Jersey, adding to a growing wave of workforce reductions at the pharma giant.

🦠 California Measles Cases Climb
The state reported its highest case count in seven years as vaccination rates continue to slip nationwide.

🏛️ HHS Budget Cuts Face Scrutiny
RFK Jr. defended his tenure and previously proposed 12.5% budget cuts, including a $5B reduction to NIH funding.

🧠 Science Corp Preps First Human Brain Implant
Max Hodak’s Science Corporation is gearing up to place its first biohybrid brain-computer interface sensor into a human patient. With a newly recruited neurosurgery leader and $230 million in fresh funding, the company is pushing toward a future where lab-grown neurons and electronics work together inside the brain. Its lead device, PRIMA, is already advancing in vision restoration, but the long-term ambition is far bigger: merging biology and hardware into a new class of medical technology.

🚀 April 21, 1972 — Apollo 16 Lands on the Moon
NASA’s Apollo 16 mission touched down in the Descartes Highlands, marking the fifth time humans walked on the Moon. Astronauts John Young and Charles Duke spent nearly three days exploring the lunar surface, conducting experiments and driving the lunar rover over 16 miles. It was one of the most science-focused Apollo missions, helping researchers better understand the Moon’s geological history before the program’s final chapter.

If you celebrated 4/20 yesterday getting higher than Apollo 16, don’t forget… today is national “random” drug test day at workplaces across the US. The question is, do you call in sick and risk raising suspicion or play it cool and show up anyway… decisions, decisions.

That’s all for today. See you Thursday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead